Foodose for iPhone plans your food around your GLP-1 dose week.
The trials, the rulings and the studies that actually affect you, summarised for a busy reader and linked to the original source. No hype. No diet talk. Just what changed and what it means for you.
On 1 October 2026 CVS Caremark restored Zepbound (tirzepatide) as a preferred option on its most common commercial formularies, alongside Wegovy. At the same time, the share of large employers covering GLP-1s for weight fell from 72% in 2025 to 60% in 2026.
In a 48-week phase 2 trial presented at EASD 2026 on 30 September, Lilly's EloraTZP, the amylin drug eloralintide combined with tirzepatide, produced up to 23.3% weight loss in adults with obesity and type 2 diabetes, against 14.8% on tirzepatide 15 mg alone.
South Korea's Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's efpeglenatide, sold as Eppe, on 7 October 2026. In a phase 3 trial of 448 Korean adults, it produced 9.02% average weight loss at 40 weeks, against 0.89% on placebo.
On 2 October 2026 the MHRA published the names of nine UK pharmacies and clinics that amended their advertising after complaints that they were promoting prescription-only weight-loss medicines to the public. It follows five in February and more than 25 businesses in 2025.
ACHIEVE-4, published in The Lancet on 30 September 2026 and presented at EASD 2026, found that Lilly's daily GLP-1 pill orforglipron (Foundayo) was not worse for the heart than insulin glargine: 4.2% against 5.0% had a major heart event over a median of 2 years.
Two phase 2 trials of petrelintide, a weekly amylin injection from Zealand Pharma and Roche, reported in the window: ZUPREME-1, published on 29 September 2026, found up to 10.7% weight loss at 42 weeks, and ZUPREME-2, announced on 7 October, found up to 9.2% at 28 weeks in type 2 diabetes.
The full TRIUMPH-1 trial of Lilly's retatrutide was published in the New England Journal of Medicine on 29 September 2026. Counting everyone who was randomised, the 12 mg dose produced 25.0% weight loss at 80 weeks against 3.9% on placebo, with less knee pain and fewer sleep apnoea events.
Lilly's phase 3 TRIUMPH-2 trial, published in The Lancet on 29 September 2026 and presented at EASD 2026, found that adults with obesity and type 2 diabetes lost 20.8% of their weight on retatrutide 12 mg over 80 weeks (18.8% counting everyone), with A1C falling by up to 1.6 points.
On 18 September 2026 Sandoz said Health Canada had approved Sandoz Semaglutide, a generic version of Ozempic for type 2 diabetes. It joins generics from Dr. Reddy's and Apotex in Canada, where Health Canada says generics are often 45 to 90% cheaper than the brand.
NYU researchers searched 92.4 million US health records for adults given a GLP-1 without type 2 diabetes or a qualifying weight. 1.13 million were, prescribing rose 15-fold from 2021 to 2025, and 35.1% had a normal BMI.
In a prespecified MRI substudy of the STEP UP trial, semaglutide reduced adipose tissue by 11.1 litres against placebo and cut fat infiltration inside the thigh muscle by 0.92 percentage points, while the change in thigh muscle volume was not statistically significant.
In 388 adults followed for six months in an endocrinology clinic, weight fell 11.3%, driven by a 8.95% fall in fat mass and a 40.6 cm2 fall in visceral fat area, while skeletal muscle fell by 1.46 kg.
A review of the evidence on GLP-1s and sedated endoscopy finds that holding a dose and continuing the medicine with 24 hours of clear liquids beforehand are both effective, with a trend towards the liquid diet being better.
In a claims study of 201,229 adults with obesity and no diabetes, only 30.7% were still persistently taking a GLP-1 twelve months after starting, and 19.6% stopped almost immediately.
Among 2,031 patients aged 10 to 17 who started a GLP-1, 16.88% were diagnosed with a nutritional deficiency or related complication within a year, most often vitamin D. Only 23.3% had a nutrition consultation within 180 days.
Novo Nordisk has said it will present 44 abstracts at the EASD annual meeting from 28 September, including real-world weight outcomes for people switching from injections to the Wegovy pill, and functional MRI work on appetite and food cue reactivity.
In a year-long trial, adults who stepped down from 10 or 15 mg of tirzepatide to 5 mg ended 16.6% below their starting weight, against 21.9% for those who stayed on their dose and 9.9% for those switched to placebo.
NYU Langone researchers used 22 gene variants that raise GLP-1 receptor activity as a stand-in for the drugs, and found about 7% added risk of male-pattern hair loss in men. Nobody in the study took a GLP-1.
In a phase 2b trial published in Nature Medicine, the oral small-molecule GLP-1 aleniglipron produced 9.0%, 10.7% and 12.1% weight loss at three doses over 36 weeks, against 0.5% on placebo.
A real-world study of 396 GLP-1 users found muscle made up 21.6% of the weight lost, and that your muscle-to-fat ratio at the start predicts your share.
New NIQ and IGD data shows 12% of UK households now include a GLP-1 user, and 80% say it changed how the whole home eats. Protein and fibre went up. Everything else went down.
A BMJ study of tens of thousands of adults links GLP-1 use to more recorded hair loss. The named mechanism is rapid weight loss and nutrient shortfalls, not the drug.
Philly Pretzel Factory, Campbell's and Honeygrow are rebuilding products around protein and fibre as GLP-1 use spreads. What the new labels are actually worth.
Bloomberg Law found hundreds of foods and supplements sold as "GLP-1 friendly". There is no federal definition of the phrase, and the FDA says it has no action planned.
A scoping review of 129 GLP-1 trials found only 10 reported dietary outcomes. Eating guidance on a GLP-1 comes from nutrition science, not from the drug labels.
A June 2026 meta-analysis of 28 trials puts tirzepatide vs semaglutide head to head. Tirzepatide won on weight, but the best drug is the one you stay on.
A new analysis of the large SURMOUNT trial found tirzepatide produced about the same weight loss, roughly 20%, whether a woman was premenopausal, perimenopausal or postmenopausal. A separate study suggests hormone therapy may add to the effect.
Semaglutide cut knee osteoarthritis pain substantially in the STEP-9 trial, and 2026 lab work hints at direct cartilage protection. What it means for women on a GLP-1.
A study of 60,000 patients found that about 40% stopped their GLP-1 within a year, but most started again soon after: 42% within a year, nearly 60% within two. The weight tends to come back, and so do they.
Wearable data from 753 adults in the All of Us programme found daily steps fell from 5,047 to 4,487, and moderate to vigorous activity from 28 minutes a day to 22, after starting a GLP-1.
The FDA has proposed formally barring pharmacies from making compounded copies of semaglutide, tirzepatide and liraglutide. It is the end of the cheaper, copied versions that filled the shortage years.
New research links GLP-1 use to a modest rise in osteoporosis: roughly 4% of users versus 3% of non-users. The likely cause is not the drug itself but the rapid weight and muscle loss that comes with it, which is preventable.
In the first randomised human trial to look at it, semaglutide slowed several markers of biological ageing by around 9%. The likely reason: less inflammation and less fat around the organs.
AstraZeneca's once-daily pill, elecoglipron, helped people with type 2 diabetes lose about 10.5% of their body weight in six months, with no injection required. The results were published in The Lancet.
More than 12,000 doctors and researchers met in New Orleans for the American Diabetes Association's 2026 sessions. The theme this year was a quiet shift: these drugs are no longer judged only by the scale.
A combination of semaglutide and an experimental drug called bimagrumab reached 22% weight loss with almost all of it coming from fat: lean mass loss was held to under 3%, versus 7.4% on semaglutide alone.
Novo Nordisk's CagriSema, which combines semaglutide with a second appetite hormone, delivered about 14% weight loss in its REIMAGINE trials. Good numbers, but analysts felt they looked modest next to the competition.
Boehringer Ingelheim's survodutide, a two-hormone drug, produced up to 16.6% weight loss over 76 weeks in its first large Phase 3 trial, adding yet another serious option to a fast-filling field.
In 26,000 adults who had both obesity and an autoimmune disease, GLP-1 users had a 44% lower risk of death, plus fewer heart events, ER visits and blood clots. Autoimmune conditions fall mostly on women.
Pfizer's experimental injection kept working when patients switched from weekly to monthly dosing, with up to 12.3% weight loss at 28 weeks. A once-a-month GLP-1 may genuinely be on the way.
A WashU and VA study mapping 175 outcomes across 2 million people links GLP-1 brain benefits to lower dementia, addiction and self-harm risk.
A study of more than 110,000 women presented at the ASCO cancer meeting found GLP-1 users were up to 47% less likely to develop breast cancer. Intriguingly, the weight loss alone did not appear to account for all of it.
A Rice University study found GLP-1 stigma and judgment runs deeper than expected: medication users were judged more harshly than dieters, or non-losers.
An investigational 1-hour endoscopic 'gut reset' (DMR) blunted weight regain after stopping Ozempic-class drugs in the REMAIN-1 trial. Promising, early, still investigational.
The FDA has approved orforglipron, sold as Foundayo, a once-daily small-molecule GLP-1 tablet for weight management that carries no food or water timing rules.
The MHRA has updated the product information for every GLP-1 and dual GLP-1/GIP medicine to cover severe acute pancreatitis, including necrotising and fatal cases, after reviewing 1,296 Yellow Card reports.
The FDA has approved a once-daily 25 mg semaglutide tablet for weight management and for reducing the risk of major cardiac events, the first GLP-1 for weight loss that is swallowed rather than injected.
An international panel of physicians, researchers and dietitians has agreed a set of nutrition and lifestyle recommendations for people taking GLP-1 medicines, built by a modified Delphi process on a review of the literature to mid-2025.
We read the journals and the trial readouts so you don't have to, then send one calm summary on Sunday mornings. Unsubscribe in one click.